Taiko Pharmaceutical Posts Higher FY2025 Profit, Plans Dividend Hike Despite Margin Pressure

Taiko Pharmaceutical Co., Ltd. ( (JP:4574) ) has issued an announcement.

Taiko Pharmaceutical reported consolidated net sales of ¥6.4 billion for the fiscal year ended December 31, 2025, a modest 1.7% increase year on year, while operating profit fell 27.1% to ¥459 million and ordinary profit dropped 29.8% to ¥482 million. Despite this margin compression, profit attributable to owners of parent rose 2.8% to ¥923 million, equity strengthened with the equity ratio climbing to 69.4%, and the company resumed shareholder returns with a year-end dividend of ¥3.30 per share.

Management forecasts a stronger top line for 2026, projecting net sales of ¥7.2 billion, up 12.5%, and a mild recovery in operating profit to ¥500 million and ordinary profit to ¥520 million, while profit attributable to owners of parent is expected to decline to ¥550 million due to one-off factors reflected in the prior year. The planned dividend increase to ¥3.50 per share underscores a shift toward a more active capital return policy, suggesting a balance between growth investment, particularly in its core OTC healthcare franchise, and enhanced shareholder rewards.

The most recent analyst rating on (JP:4574) stock is a Hold with a Yen315.00 price target. To see the full list of analyst forecasts on Taiko Pharmaceutical Co., Ltd. stock, see the JP:4574 Stock Forecast page.

More about Taiko Pharmaceutical Co., Ltd.

Taiko Pharmaceutical Co., Ltd., listed on the Tokyo Stock Exchange under code 4574, operates in the pharmaceutical industry and is best known for products such as Seirogan. The company focuses on over-the-counter medicines and related healthcare products, serving domestic and international markets with an emphasis on gastrointestinal and general consumer health solutions.

Average Trading Volume: 119,415

Technical Sentiment Signal: Sell

Current Market Cap: Yen14.92B

See more insights into 4574 stock on TipRanks’ Stock Analysis page.